tacrolimus topical / Generic mfg. - LARVOL DELTA

Outcomes of stem cell transplantation in pediatric and adolescent/young adult patients with trisomy 21: A single-center experience (ASH 2025) - "All patients received a myeloablative conditioning with post-transplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis...One patient developed steroid refractory grade III skin GvHD requiring prednisone, ruxolitinib, and topical tacrolimus, and experienced eventual improvement with extracorporeal photopheresis... Here we describe three patients with T21 who underwent HSCT for relapsed/refractory leukemia. Two patients are surviving, including one with multiply relapsed disease who had initial graft failure, and remains disease free 2 years and 7 months following HSCT. Toxicities following HSCT were manageable and did not significantly impact engraftment."

Clinical • Acute Kidney Injury • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • CNS Disorders • Developmental Disorders • Endocrine Disorders • Epilepsy • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Nephrology • Pediatrics • Transplantation • TP53

Hiding beneath the surface: Paraneoplastic pemphigus as a rare presentation of follicular lymphoma (ASH 2025) - "He initiated treatment with bendamustine and obinutuzumab and tolerated three of six planned cycles...The observed rapid improvement with topical tacrolimus supports a T cell–mediated pathogenesis... PNP is an exceptionally rare autoimmune manifestation of follicular lymphoma and should be considered in patients with refractory erosive mucositis and new lymphoproliferative diagnoses, even when conventional diagnostic tests are inconclusive. Prompt recognition, interdisciplinary management, and consideration of T cell–targeted therapy are essential, especially in cases with respiratory involvement. Further research into immunosuppressive strategies for lichenoid PNP is needed."

Cognitive Disorders • Dermatology • Dermatopathology • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lichen Planus • Lymphoma • Mucositis • Non-Hodgkin’s Lymphoma • Pneumonia • Pulmonary Disease • Respiratory Diseases • CD8

Topical cyclosporine vs tacrolimus for ocular GVHD prophylaxis after outpatient allogeneic hematopoietic stem cell transplantation: A Phase I–II trial (ASH 2025) - P1/2 | "This study evaluated the safety,tolerability and early efficacy of topical tacrolimus (Tac) vs cyclosporine (Cys) for oGVHD prevention in theoutpatient alloHCT setting.MethodsNon-blinded phase I–II trial (NCT06348602) in patients >18 years undergoing outpatient peripheral bloodalloHCT from matched sibling or haploidentical donors...Systemic GVHD prophylaxis included post-transplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate mofetil.Ophthalmologic evaluations were performed every 3 months using NIH and ICCGVHD criteria.Tolerability was defined as relative (with adverse effects but no discontinuation) or absolute (treatmentwithdrawal)...These findings support the feasibility ofusing topical immunomodulators for oGVHD prophylaxis in outpatient alloHCT. Longer follow-up isneeded to assess sustained efficacy."

Clinical • P1/2 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Depression • Dermatology • Dry Eye Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myeloproliferative Neoplasm • Ocular Infections • Ophthalmology • Pruritus • Psychiatry • Transplantation • CD34

BI24 A case of refractory pyoderma gangrenosum successfully treated with upadacitinib. (PubMed, Br J Dermatol) - "The patient also had enteropathic arthritis, initially controlled with infliximab and azathioprine...Initial treatments were unsuccessful, including wound dressings, topical and systemic corticosteroids (intravenous methylprednisolone), topical tacrolimus and antibiotics. Ciclosporin was introduced when she did not respond to escalated doses of infliximab...This case highlights the importance of collaborating with other specialties regarding alternative treatments that are not available for dermatology conditions. Further studies are needed to evaluate the efficacy of Janus kinase inhibitors in PG."

Journal • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Pyoderma Gangrenosum • Rheumatoid Arthritis • Rheumatology

Exploratory Evaluation of Topical Tacrolimus for Prevention of Breast Cancer-Related Arm Lymphedema: A Multicenter Non-Randomized Pilot Study. (PubMed, Cancers (Basel)) - "Adverse events were mild and manageable, with no serious events reported. While topical tacrolimus did not significantly reduce the incidence of lymphedema, exploratory patterns in symptom onset and quality-of-life measures indicate that further investigation in larger randomized trials may be warranted."

Journal • Breast Cancer • Oncology • Solid Tumor

Case series of mycosis fungoides with marked clinical resemblance to seborrheic dermatitis (ISDS 2025) - "Six months later, the lesion had progressed into a dry, cracked plaque with thick scale that was refractory to topical hydrocortisone, clobetasol, and ketoconazole...Seven months later, the lesion proved refractory to tacrolimus, topical hydrocortisone, and bexarotene (75 mg) that had been prescribed for another MF lesion...Taken together, these three cases highlight key clinical features that help distinguish SD-like MF from SD: unilateral presentation, asymmetry, poor response to standard SD therapies, and history of MF; histopathology may be diagnostic, as in cases 1 and 2, or equivocal, as in case 3. For patients with MF and new lesions or rashes, we thus recommend a combination of total body skin exams, repeat biopsies, and molecular analysis for clonality."

Clinical • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Mycosis Fungoides • Oncology • Psoriasis • Seborrheic Dermatitis

Roflumilast as an Emerging Treatment for Oral Lichen Planus: A Case Series (ISDS 2025) - "Management typically relies on off-label medications such as topical corticosteroids (TCS), systemic corticosteroids, calcineurin inhibitors (TCI), oral retinoids, and cyclosporine. Phosphodiesterase-4 (PDE-4) inhibitors, including apremilast and roflumilast, have recently been explored for OLP...Case Series: We present three cases of OLP in patients aged 65, 66, and 69, each with recurrent flares after multiple prior therapies, including TCS, TCI, hydroxychloroquine, and minoxidil...Adjunctive therapy included isotretinoin in two cases and topical tacrolimus swish and spit in the third case... This case series suggests that OR may be an effective treatment option for OLP. Further studies are warranted, as only one prior investigation of OR in OLP exists."

Clinical • Anorexia • Dermatitis • Dermatology • Dermatopathology • Gastrointestinal Disorder • Immunology • Inflammation • Lichen Planus • Movement Disorders • Mucositis • Pruritus • CD8

Lichen Aureus in a Patient with Prior Methotrexate Therapy: Successful Management with Topical Tacrolimus and Adjunctive Rutin/Vitamin C (ISDS 2025) - "She was started on betamethasone dipropionate 0.05% cream twice daily. While lichen aureus is typically idiopathic, the patient's prior methotrexate use raises the possibility that immune modulation may have contributed to lesion development, though a direct causal link cannot be established. Notably, this case demonstrates successful management using topical tacrolimus as a steroid-sparing agent, combined with adjunctive oral rutin and vitamin C to support vascular integrity, an approach rarely reported in the literature that may provide a useful strategy for persistent or refractory lesions."

Clinical • Dermatitis • Dermatology • Immune Modulation • Immunology • Infectious Disease • Pruritus • Respiratory Diseases • Tuberculosis

Lymphocytoma cutis treated with topical tacrolimus (ISDS 2025) - "Identified triggers include acupuncture, piercings, tattoos, medications (e.g., phenytoin), vaccinations, viral infections, insect bites, and Borrelia burgdorferi, though many cases are idiopathic...Current treatments—including systemic corticosteroids, intralesional injections, superficial radiotherapy, PUVA, photodynamic therapy, cryosurgery, and hydroxychloroquine—show variable efficacy, with no consensus on optimal management... This case highlights the potential utility of topical tacrolimus in LC, expanding therapeutic options for this challenging condition. Given the limited data on tacrolimus use in LC, further studies are warranted to establish efficacy and safety, particularly for lesions in cosmetically sensitive areas."

CNS Disorders • Dermatology • Hematological Malignancies • Infectious Disease • Lyme Disease • Lymphoma • Pruritus

A humanized xenotransplant model reveals IgG4 and HSP70 as co-drivers of vitiligo and predicts clinical drug responses (ISDS 2025) - "Therapeutically, topical tacrolimus and ruxolitinib cream produced repigmentation in ∼30% and ∼70% of lesions respectively, consistent with clinical experience; however, epidermal TRM persisted after ruxolitinib, retaining cytokine competence. Senescence and mitochondrial dysfunction are early, supportive features that increase model relevance to human disease. The platform therefore provides a translationally relevant tool for dissecting mechanisms and testing therapies that target humoral-cellular cooperation, danger signaling, and cellular senescence in vitiligo."

Clinical • Dermatology • Immunology • Metabolic Disorders • Transplantation • Vitiligo • CAT • CD8 • IFNA1 • IFNG • IL15 • IL18 • ITGAX • MICA • NKG2D • SIRT1 • Tyrosinase

Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. (PubMed, Int J Mol Sci) - "Ciclosporin, a calcineurin inhibitor, remains a valuable immunosuppressant for long-term cAD management, while topical tacrolimus provides localized benefits...Consequently, they enable improved quality of life for affected dogs and their owners. Future strategies will likely focus on patient stratification and personalized approaches based on immunological endotypes."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

The mouth as a window: A multi-center retrospective study of oral extraintestinal manifestations of IBD and their management. (PubMed, Med Oral Patol Oral Cir Bucal) - "OEIMs are common in IBD and can influence treatment decisions. Colchicine and topical agents demonstrated benefit in selected cases. These findings support multidisciplinary care and inform a therapeutic algorithm for OEIM management in IBD."

Journal • Retrospective data • Anesthesia • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus (clinicaltrials.gov) - P1 | N=160 | Completed | Sponsor: University of Seville

New P1 trial • Dry Eye Disease • Ophthalmology

Clinical applications of tacrolimus in the treatment of ocular diseases: a narrative literature review. (PubMed, Int Ophthalmol) - "Tacrolimus is a practical steroid‑sparing therapy for severe ocular surface inflammation. Priority trials should be formulation‑specific with standardized outcomes and pharmacokinetic endpoints, alongside pediatric safety registries and head‑to‑head comparisons versus cyclosporine 2% and soft steroids."

Journal • Review • Conjunctivitis • Dry Eye Disease • Graft versus Host Disease • Immunology • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Transplantation • Uveitis

Treatment-Resistant Eosinophilic Spongiosis Dermatitis in a Patient With Various Comorbidities: A Case Report. (PubMed, Cureus) - "Alongside receiving a thorough cardiovascular exam workup, the patient tried numerous treatments for his rash and the pruritus, including topical triamcinolone, tacrolimus ointment, steroid injections, hydroxyzine, amitriptyline, and, most recently, dupilumab therapy. This case report highlights the complexity of ongoing assessment and treatment, offering guidance for the care of patients with similar presentations. Educational insights obtained from this report include maintaining broad differential diagnoses, the influence of neuropsychiatry and cardiology in dermatology, and the importance of multidisciplinary care."

Journal • Atopic Dermatitis • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Mood Disorders • Pain • Pruritus • Psychiatry • Pulmonary Disease • Venous Ulcer

Pruritis Ani. (PubMed, Surg Clin North Am) - "Early and frequent discussion of expectations can help to protect the physician-patient relationship and guide treatment. This article will serve to outline the etiologies, diagnostic workup, and therapeutic modalities essential to the treatment of pruritus ani."

Journal • Review • Dermatology • Pruritus

Copper Intrauterine Device-Associated ANCA Vasculitis: Rare Entity or a Coincidence? (KIDNEY WEEK 2025) - "Case Description A 50-year-old-female with a past medical history of hyperlipidemia, asthma, migraine, mild obesity, and pre- diabetes on metformin and empagliflozin presented to the clinic for evaluation of albuminuria of 139 mg/gm of creatinine (90 ml/min/1.73m2)...She was prescribed topical tacrolimus and clindamycin, along with oral doxycycline...Cutaneous small vessel vasculitis has been documented in association with chronic hepatitis A or C, oral contraception, hydralazine, propylthiouracil, allopurinol, β-lactams, streptokinase, tamoxifen, influenza vaccines, and environmental risk factors (silica exposure, farming, and chronic colonization with Staphylococcus aureus). One other case report has proposed a possible link between a copper-IUD and ANCA-associated retinal vasculitis, which was resolved following IUD removal. One caveat is the lack of a kidney or skin biopsy, as our patient declined."

ANCA Vasculitis • Asthma • CNS Disorders • Dermatitis • Dermatology • Diabetes • Dyslipidemia • Genetic Disorders • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Influenza • Long-acting Reversible Contraceptives • Metabolic Disorders • Migraine • Obesity • Ocular Inflammation • Psoriasis • Renal Disease • Respiratory Diseases • Vasculitis

Topical tacrolimus for superficial tufted angioma: A randomized clinical trial. (PubMed, J Am Acad Dermatol) - "5 FIGURES: 0."

Clinical • Journal

Impact of Dietary Modifications on Severe Treatment-Resistant Atopic Dermatitis (ACAAI 2025) - "Her disease was refractory to topical and systemic steroids, topical tacrolimus, dupilumab, upadacitinib, and UVB phototherapy...She initially responded to cyclosporine but quickly recrudesced. Tapinarof provided modest improvement but required more dosing than dispensations permitted...Discussion Guidelines recommend against elimination diets in AD given risk of food allergy development. The potential benefits of low-carbohydrate, preservative-free and plastic-free diets warrant further investigation."

Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Eosinophilia • Food Hypersensitivity • Immunology • CARD11 • IL13 • IL5

Breaking Through the Mucosal Wall: Topical Tacrolimus for Refractory Esophageal Lichen Planus (ACG 2025) - "Over the subsequent months, the patient was trialed on approximately 12-week courses of the following: twice daily high-dose proton pump inhibitor (PPI), two different formulations of topical corticosteroids equivalent to budesonide 2 mg twice daily, oral tacrolimus 2 mg twice daily, and hydroxychloroquine 200 mg daily. Given the difficulty of treating refractory ELP, this case may provide clinicians with another medication that may be utilized when other therapies have failed.Figure: Figure 1: Initial endoscopic findings in the proximal (1a.), mid (1b.), and distal (1c.) esophagus and histopathology demonstrating lymphocyte predominant esophagitis with dyskeratotic cells (1d,1e,1f)Figure: Figure 2. Follow up endoscopic findings after 3 months of esophageal suspension tacrolimus (2a, 2b)"

Dermatology • Dermatopathology • Gastrointestinal Disorder • Gynecology • Hodgkin Lymphoma • Inflammation • Lichen Planus

Assessing the Use of Topical Tacrolimus Therapy in Patients With an Ileal Pouch-Anal Anastomosis (ACG 2025) - "Introduction: Treatments for pouchitis and cuffitis in patients with an ileal pouch-anal anastomosis (IPAA) are similar to those for pre-surgical inflammatory bowel disease (IBD), but over 10% of patients still experience treatment failure. A total of 95 patients met eligibility criteria: 9 in the tacrolimus suppository cohort and 86 in the control group. The tacrolimus cohort had a shorter disease duration before colectomy and was more likely to use infliximab and upadacitinib post-operatively, but the groups were otherwise similar in demographics, clinical variables, and follow-up (Table 1). Overall, 48 (51.6%) patients showed endoscopic improvement of pouch and/or cuff inflammation within 12 months, with no significant difference between cohorts (71.1% vs."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Tacrolimus-loaded chitosan-based nanoparticles as an efficient topical therapeutic for the effective treatment of atopic dermatitis symptoms (ISAD-RAJKA 2025) - "Importantly, an in vivo AD mouse model revealed that topical TAC@CNP containing ~1/10 of the dose of TAC found in commercially used Protopic® Ointment exhibited similar anti-inflammatory activity to that of the commercial product. TAC@CNP represents a potential therapeutic strategy for the management of AD"

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Case of Morbihan Disease Complicating Refractory Facial Lesions in Atopic Dermatitis (ISAD-RAJKA 2025) - "These symptoms were resistant to topical corticosteroids and tacrolimus ointment...Moribihan disease should be considered as a potential cause of refractory facial lesions in atopic dermatitis. Recognition and accurate diagnosis of this condition are crucial for determining appropriate treatment strategies."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lichen planus pigmentosus inversus after Pfizer-BioNTech COVID-19 vaccination: A rare case report. (PubMed, Diagn Microbiol Infect Dis) - "This study describes a case of a 30-year-old female who developed Lichen Planus Pigmentosus Inversus (LPPI) two weeks after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine...The patient followed up for two months, during which the patient received topical tacrolimus 0.1 % and corticosteroids, and pigmentation declined within three weeks...This case highlights the importance of recognizing the potential of LPPI as a rare variant of lichen planus that occurs following Pfizer-BioNTech COVID-19 vaccination. Healthcare providers, especially dermatologists, should maintain awareness of this potential adverse effect to ensure prompt recognition and appropriate management."

Journal • Dermatology • Dermatopathology • Infectious Disease • Lichen Planus • Novel Coronavirus Disease

Drug Utilization and Medication Adherence: A Data-Driven Analysis of Drugs with Different Routes of Administration Applied in Atopic Dermatitis. (PubMed, Pharmaceutics) - "Dupilumab demonstrated a significantly longer median treatment duration compared to tacrolimus (4.4 vs. 2.6 months; p < 0.01). The observed differences in adherence patterns between topical tacrolimus and subcutaneous dupilumab suggest that distinct contextual and behavioral factors influence patient adherence during therapy."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology